Advertisement

Organisation › Details
LabGenius Ltd.
LabGenius is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius operates under a hybrid business model that involves partnering with large biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. *
![]() |
Start | 2012-08-17 established |
![]() |
Industry | synthetic biotechnology |
Industry 2 | artificial intelligence (AI) / machine learning (ML) | |
Street | 100 Drummond Road The Biscuit Factory, G04 Cocoa Studios | |
City | SW7 2AZ London | |
Address record changed: 2024-05-22 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: LabGenius. (5/21/24). "Press Release: LabGenius Raises £35 Million Led by M Ventures to Further Develop Its ML-driven Antibody Discovery Platform and Progress a Pipeline of Assets Towards the Clinic". London. | ||
Record changed: 2024-05-22 |
Advertisement

More documents for LabGenius Ltd.
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top